2019 E-News

Choose the issue you would like to read below:

PDSA e-News: November 26, 2019

CONTENTS:

Immune Thrombocytopenia: Are we stuck in the mud or is there light at the end of the tunnel?
Clinical trial for early use of eltrombopag in pediatric patients with ITP

Read more...

PDSA e-News: October 29, 2019

CONTENTS:

Splenectomy in the context of new medical therapies for ITP
Nplate® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia

Read more...

PDSA e-News: September 30, 2019

CONTENTS:

Prognostic factors for Immune Thrombocytopenia remission after laparoscopic splenectomy
Comparison of first-line treatments for newly diagnosed Immune Thrombocytopenia

Read more...

PDSA e-News: August 30, 2019

CONTENTS:

Physicians’ Perceptions on Causes of Secondary ITP And the Leading Causes of Misdiagnosis in Both Primary and Secondary ITP
Retrospective Study Examines The Treatment Results of Sequentially Switching Thrombopoietic Receptor-Agonists In Immune Thrombocytopenia Patients

Read more...

PDSA e-News: July 23, 2019

CONTENTS:

Long-term overuse of corticosteroids in the real-world treatment of patients with immune thrombocytopenia
ITP patient perceptions on splenectomy outcomes

Read more...

PDSA e-News: June 30, 2019

CONTENTS:

Patient and Physician Perceptions on Treatment Approaches
FDA approves new drug “Doptelet” for treatment of chronic ITP

Read more...

PDSA e-News: May 31, 2019

CONTENTS:

Characteristics, Risk Factors, and Management of Venous Thromboembolism in ITP
Prospective Study Examines the Variability of Second-Line Treatment Outcomes In Children With ITP

Read more...

PDSA e-News: April 29, 2019

CONTENTS:

High-Dose Dexamethasone Displays The Ability To Reduce Elevated Interleukin-16 Levels In Adult Immune Thrombocytopenia Patients
An Open-Label Phase 3 Extension Study Examines The Effects Of Long-term Fostamatinib (TavalisseTM) Treatment On Adult ITP Patients

Read more...

PDSA e-News: March 31, 2019

CONTENTS:

Increased Monitoring Should Be Utilized When Receiving Immune Checkpoint Inhibitors
Posttransfusion Purpura with Antibodies Against Human Platelet Antigen-4a following Checkpoint Inhibitor Therapy: a Case Report and Review of the Literature

Read more...

PDSA e-News: February 28, 2019

CONTENTS:

Retrospective Study Finds That The Combination Therapy of Rituximab and Cyclophosphamide Displays Increased Therapeutic Effects Compared To Each Drugs Individual Therapeutic Effects on Patients Suffering From Refractory ITP
Chidamide Study Displays Potential For Novel Therapies and Multiple Pathways For ITP Intervention

Read more...

PDSA e-News: January 31, 2019

CONTENTS:

FDA Approves Romiplostim (N-Plate) as a Treatment Option for Pediatric Patients with Immune Thrombocytopenia
Berberine May Offer ITP Patients Suffering from Corticosteroid Resistance Induced by Gut Microbiota Imbalance a New Option for Therapy

Read more...

Donate

make a one-time donation
start your monthly gift today
donate in honor of someone
donate in memory of someone
donate to the research program
donate to the pdsa college scholarship program
why your donation matters
other ways to donate

About PDSA

leadership
staff
board of directors
medical advisory board
financials
contact us

Stay Informed

sign-up on pdsa.org
newsroom
pdsa e-news
general itp faq

IMPORTANT!

The Platelet Disorder Support Association does not provide medical advice or endorse any medication, vitamins or herbs. The information contained herein is not intended nor implied to be a substitute for professional medical advice and is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment, discontinuing an existing treatment and to discuss any questions you may have regarding your unique medical condition.

Platelet Disorder Support Association
8751 Brecksville Road, Suite 150, Cleveland, Ohio 44141
Phone: 1-87-PLATELET | 877-528-3538 (toll free) | or 440-746-9003
E-mail: pdsa@pdsa.org

© Copyright 1997 - 2019, Platelet Disorder Support Association. All rights reserved. The Platelet Disorder Support Association is a 501(c)3 organization and donations are tax deductible to the fullest extent allowed by law.

Privacy Policy and Terms of Use